New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
06:03 EDTVNDAVanda pullback a buying opportunity, says Piper Jaffray
Piper Jaffray recommends using the post-earnings pullback in shares of Vanda Pharmaceuticals as a buying opportunity. Piper says Hetlioz is launching well and that it sees no reason to back off its bullish stance or $25 price target. The firm reiterates an Overweight rating on the name.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
13:21 EDTVNDAVanda Pharmaceuticals volatility increases
Vanda Pharmaceuticals February call option implied volatility is at 87, March is at 91; compered to its 26-week average of 79 according to Track Data, suggesting large price movement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use